CLINICAL_TRIALS ClinicalTrials.gov record update

Phase 1 Dose Escalation, Multi-tumor Study to Assess the Safety, Tolerability and Antitumor Activity of Genetically Engineered MAGE-A4ᶜ¹º³²T in HLA-A2+ Subjects With MAGE-A4 Positive Tumors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03132922
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:39:21.644596+00:00
Published At: 2024-01-22T00:00:00+00:00
Record Updated At: 2024-01-22
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Urinary Bladder Cancer", "Melanoma", "Head and Neck Cancer", "Ovarian Cancer", "Non-Small Cell Lung Cancer", "Esophageal Cancer", "Gastric Cancer", "Synovial Sarcoma", "Myxoid Round Cell Liposarcoma", "Gastroesophageal Junction"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2024-01-22"
protocolSection.identificationModule.nctId: "NCT03132922"
protocolSection.identificationModule.officialTitle: "Phase 1 Dose Escalation, Multi-tumor Study to Assess the Safety, Tolerability and Antitumor Activity of Genetically Engineered MAGE-A4\u1d9c\u00b9\u00ba\u00b3\u00b2T in HLA-A2+ Subjects With MAGE-A4 Positive Tumors"
protocolSection.statusModule.overallStatus: "ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.